Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated ...

Rapport Therapeutics advances RAP-219 into Phase 3 epilepsy

Detailed price information for Rapport Therapeutics Inc (RAPP-Q) from The Globe and Mail including charting and trades.

Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the ...

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarte ...
Frontiers

Cortical stimulation and epilepsy: Network physiology insights for diagnosis and therapy

The field of epilepsy research has rapidly evolved with an appreciation that seizures arise from dysfunctions in distributed ...
BMJ Open

Effects of alcohol misuse on the evolution of anxiety during the COVID-19 pandemic in France: results from CONFINS cohort

Objectives to describe the evolution of anxiety during the COVID-19 pandemic in France and to assess whether it differed according to pre-existing alcohol misuse. Design A prospective longitudinal ...